CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Otago Innovation Ltd. engages in research and developments. The firm is a University of Otago company responsible for developing and commercializing the University's intellectual property. The company was founded in 2002 and is headquartered in Dunedin, New Zealand.

Upstream Medical Technologies is a medical diagnostics company specializing in cardiovascular disease testing. It develops a cardio endocrine bio-markers designed for accurate diagnosis of heart disease and associated complications, enabling doctors to detect and treat heart diseases without causing much harm to the patient. Its patented technology is based on specialist protein peptides. Upstream's pipeline of tests enables earlier diagnosis for improved patient recovery. The diagnostics company was founded by Chris Pemberton in Seacliff, Otago in 2015.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Manufactures pharmaceuticals and diagnostic substances

Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative "firsts," Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, They dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.

Hangzhou Jinsai Biomedical Technology Co., Ltd., established on 2021-11-01, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Development of Human Gene Diagnosis and Therapy Technology;R&D and application of cell technology;New material technology research and development;Engineering and Technology Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Part of Parker-Hannifin Corp., Chomerics, Inc. is a company headquartered in Woburn, MA, involved in adhesives and sealants. Parker-Hannifin Corp. acquired Chomerics, Inc. from W. R. Grace & Co.-Conn. on October 04, 1994 for $40 million.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Olatec Therapeutics LLC is an American company located in New York, NY. The firm provides clinical development of anti-inflammatory pharmaceuticals. It was founded by Damaris B. Skouras, he is the current CEO of the firm.\nThe company says this about itself: Olatec is a privately held, Phase 2/3 clinical-stage biopharmaceutical company developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases known to be mediated by IL-1 (see list of clinical trials to-date, here). In addition to the lead compound, dapansutrile, Olatec’s platform of proprietary compounds includes OLT Analogues being screened as viable drug candidates. A portfolio of intellectual property registrations protecting Olatec’s compounds consists of over 130 patents granted, covering dapansutrile and OLT Analogues. Olatec’s drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology and has been involved in the discovery and development of first-line inflammation treatments in the market today.